


The Neuro4D Conference 2020

Atrium Hotel – Mainz, Germany – Close to Frankfurt Airport



DEGENERATIVE
DISEASE
DRUG
DISCOVERY

**MONDAY
MAY 11TH**

OPENING

PANEL 1

COFFEE

PANEL 2

LUNCH

08:00		
Registration and Joint Breakfast (Please attach Posters.)		
09:00		
Opening of the Conference		
09:15 – 09:45		
Scientific Introduction: Alzheimer's Disease	Protein misfolding-specific immunotherapies for neurodegeneration	Neil Cashman Department of Neurology, UBC, Canada
09:45 – 10:45		
AD Disease Mechanism	Structure of A β -Fibrils from human AD brain and implication for function	Marcus Fändrich Ulm University, Germany
	Apolipoprotein E is an amyloid-inhibitor with broad specificity	Anders Olofsson Umeå University, Sweden
	Brain inflammation – an important part of AD disease progression	Michael Harte University of Manchester, UK
Panel Q&A of Session Speakers <i>Chair: Neil Cashman, Department of Neurology, UBC, Canada</i>		
10:45 – 11:30		
Coffee Break, Exhibition & Poster Session (All Presenters will be at their Posters for Discussion.)		
11:30 – 12:30		
AD Drug Discovery	Reduction of amyloid seeding by small molecules	Erich Wanker Neuroproteomics and Molecular Mechanisms of Neurodegenerative Diseases, Max Delbrück Center, Germany
	Elimination of misfolded A β by PRI-002 reverses cognition deficits and slows neurodegeneration in preclinical models of AD	Dieter Wilbold Priavoid, Germany
	Predicting outcomes in Alzheimer's clinical trials	Tuomas Knowles Fluidic, UK
Panel Q&A of Session Speakers <i>Chair: Neil Cashman, Department of Neurology, UBC, Canada</i>		
12:30 – 13:30		
Lunch		

The Neuro4D Conference 2020

Atrium Hotel – Mainz, Germany – Close to Frankfurt Airport



DEGENERATIVE
DISEASE
DRUG
DISCOVERY

**MONDAY
MAY 11TH**

13:30 – 14:00

**Scientific Introduction:
Parkinson's Disease**

Parkinson's disease: A disease with many faces

Tiago Outeiro

University Medical Center
Goettingen, Germany

PANEL 3

14:00 – 15:00

**PD Disease
Mechanism**

Role of LRRK2 in maintaining nuclear envelope integrity and implications for Parkinson's disease

Simone Engelender

Technion, Israel

The mitochondrial genome at the interface between mitochondrial dysfunction and inflammation in Parkinson's disease

Anne Grünewald

Luxembourg Centre for
Systems Biomedicine,
Luxembourg

PD Model

Characterization of α -synuclein-fibril-induced models of PD and their use in preclinical drug development

James Koprich

Atuka, Canada

Panel Q&A of Session Speakers

Chair: Tiago Outeiro, University Medical Center Goettingen, Germany

COFFEE

15:00 – 17:00

Coffee Break, Exhibition & Poster Voting
(All Presenters will be at their Posters for Discussion. Please vote for the best poster!)
One on One Meetings

PANEL 4

17:00 – 18:00

PD Biomarker

Parkinson's disease progression pathology:
New insides for biomarker discovery?

Walter Schulz-Schaeffer

Neuropathology, Saarland
University, Germany

PD Drug Discovery

Development of an α -synuclein aggregate-selective active immunotherapy for the treatment of synucleinopathies – from preclinical to clinical stages

Günther Staffler

Affiris, Austria

CNS-focused drug design – success stories

Michael Thormann

Origenis, Germany

Panel Q&A of Session Speakers

Chair: Tiago Outeiro, University Medical Center Goettingen, Germany

TASTING

18:00 – 19:00

Local Craft Beer Tasting in the Foyer
Poster Voting
(Please vote for the best poster!)

DINNER

19:00 – 22:00

Dinner
We will have a seated barbeque dinner, accompanied by fitting local wines!
Depending on the weather, we will be on the hotel terrace, or in the adjacent room.

END OF THE FIRST DAY

The Neuro4D Conference 2020

Atrium Hotel – Mainz, Germany – Close to Frankfurt Airport



DEGENERATIVE
DISEASE
DRUG
DISCOVERY

**TUESDAY
MAY 12TH**

PANEL 5

07:30		
Joint Breakfast Exhibition & Poster Session		
08:30		
Scientific Introduction: Other proteopathic neurodegenerations	Common pathophysiological mechanisms of neurodegenerative diseases	Antje Willuweit Inst. F. Neurosciences & Medicine, Jülich, Germany
09:00 – 10:00		
Disease Mechanism	The importance of protein localization in Spinocerebellar Ataxia Type 3: From molecular insight to a treatment strategy	Thorsten Schmidt Medical Genetics, Tübingen, Germany
	Toxic fragments, proteolytic cleavage, and calpains in the molecular pathogenesis of polyglutamine disorders – a unifying mechanism as a therapeutic target	Jonasz Weber Human Genetics, Ruhr University Bochum, Germany
ALS Model	Validating a reliable ALS mouse model for drug testing	Vera Niederkofler QPS, Austria
Pannel Q&A of Session Speakers <i>Chair: Antje Willuweit, Inst. F. Neurosciences & Medicine, Jülich, Germany</i>		
10:00 – 11:00		
Coffee Break, Exhibition & Poster Voting (All Presenters will be at their Posters for Discussion. Final chance to rate the best poster!) One on One Meetings		
11:00 – 12:30		
Enabling Technology	Cellular reprogramming using opti-ox to generate human neuronal models	Lydia Turkson Bit Bio, UK
	tbd	tbd
	Public data resource and mining tools of AHCODA-DB discriminate neurodegeneration from healthy ageing in mice	Maarten Loos Sylics, The Netherlands
	Characterization and reproducibility of rodent models for AD and PD	Terina N. Martinez Taconic Biosciences, USA
Biomarkers	Biomarkers help to advance new therapeutics for neurodegenerative diseases	Cecilia Gabriel Gracia Servier, France
Pannel Q&A of Session Speakers <i>Chair: Antje Willuweit, Inst. F. Neurosciences & Medicine, Jülich, Germany</i>		

The Neuro4D Conference 2020

Atrium Hotel – Mainz, Germany – Close to Frankfurt Airport



DEGENERATIVE
DISEASE
DRUG
DISCOVERY

**TUESDAY
MAY 12TH**

12:30 – 13:30

Lunch

PANEL 7

13:30 – 14:00

Clinical Studies in
Neurodegenerative
Diseases

Are disease modifying treatments finally here?

Oliver Peters
Charité, Berlin, Germany

14:00 – 15:00

AD Clinical Trial

Lessons learned from developing gantenerumab as
disease modifying therapy

Martin Traber
Roche, Switzerland

Clinical Phase I data of PRI-002, an antiprionic AD
drug candidate

Dieter Wilbold
Priavoid, Germany

BAN2401, an Anti-A β Soluble Aggregate Monoclonal
Antibody, Removes Amyloid Plaque and Reduces
Clinical Decline in Early Alzheimer's Disease

Chad Swanson
Eisai

Pannel Q&A of Session Speakers
Chair: Oliver Peters, Charité, Berlin, Germany

COFFEE

15:00 – 15:30

Coffee Break
Final Poster Session & Price for the Best Poster

15:30

Pannel Discussion:
What are the hottest developments for Neurodegenerative Disease Treatment?

WRAP-UP

16:20 – 16:30

Summary and Wrap-Up of the Conference

END OF THE CONFERENCE AND DEPARTURE